Treatment of Chronic Hepatitis C Virus During Pregnancy

Official Title
Safety, Tolerability, and Outcomes of Velpatasvir/SofosbuviR in Treatment of Chronic Hepatitis C Virus during Pregnancy (STORC), pregnant woman

This study involves evaluating a medication for hepatitis C in pregnant women. 

If you are a pregnant woman with chronic hepatitis C and you join the study, you are consenting to enroll yourself and your baby after he/she is born.

Maternal participants will have 7 visits over approximately 7 months. Infant participants have four visits over approximately the first year of life.

Could this study be right for you?

(This is not a complete list)  

- Must be  18 - 45 years of age

Chronic HCV infection of at least 6 months

- Singleton pregnancy at 20 + 0 to 30 + 0 weeks’ gestation

Documented negative Hepatitis B testing for current infection (negative HBsAg test) prior to enrollment

If living with HIV, must be on antiretroviral therapy


Exclusion Criteria (not a complete list)

Plans to relocate away from the study site area in the next 16 months and unable/unwilling to return for study visits

History of cirrhosis

Known fetal chromosomal abnormality prior to enrollment

Age Range
18 - 45